Bristol-Myers Squibb and Samsung BioLogics agree 10-year manufacturing partnership
Samsung BioLogics will manufacture an antibody cancer drug for Bristol-Myers Squibb
Bristol-Myers Squibb has entered into a 10-year agreement with Samsung BioLogics under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
No financial details have been disclosed.
Technology transfer and trial production will begin this month (July) with commercial production starting immediately after regulatory approval has been given.
‘Our agreement with Samsung is an important part of our company’s overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world,’ said Louis Schmukler, President, Global Manufacturing & Supply, Bristol-Myers Squibb. ‘This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products.’
Tae-Han Kim, President and CEO of Samsung BioLogics, said: ‘The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry.’